Amyotrophic lateral sclerosis and intestinal microbiota—toward establishing cause and effect

References

• Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013 Mar;12(3):310–322. doi:10.1016/S1474-4422(13)70036-X.
   Google Scholar
• Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson’s disease. Cell. 2016 Dec;167(6):1469–1480.e12. doi:10.1016/j.cell.2016.11.018.
   Google Scholar
• Sharon G, Cruz NJ, Kang D-W, Gandal MJ, Wang B, Kim Y-M, Zink EM, Casey CP, Taylor BC, Lane CJ, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell. 2019 May;177(6):1600–1618.e17. doi:10.1016/j.cell.2019.05.004.
   Google Scholar
• de Theije CGM, Wopereis H, Ramadan M, van Eijndthoven T, Lambert J, Knol J, Garssen J, Kraneveld AD, Oozeer R. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun. 2014 Mar;37:197–206. doi:10.1016/j.bbi.2013.12.005.
   Google Scholar
• De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, Cristofori F, Guerzoni ME, Gobbetti M, Francavilla R. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013 Oct;8(10):e76993. doi:10.1371/journal.pone.0076993.
   Google Scholar
• Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, Cionci NB, Gaggìa F, Lucenti A, Bersano E, et al. Potential role of gut microbiota in ALS pathogenesis and possible novel therapeutic strategies. J Clin Gastroenterol. 2018;52(Suppl 1):S68–S70. Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017. doi:10.1097/MCG.0000000000001042.
   Google Scholar
• Erber AC, Cetin H, Berry D, Schernhammer ES. The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci. 2019 Dec:1–9. DOI:10.1080/00207454.2019.1702549.
   Google Scholar
• De Angelis M, Francavilla R, Piccolo M, De Giacomo A, Gobbetti M. Autism spectrum disorders and intestinal microbiota. Gut Microbes. 2015;6(3):207–213. doi:10.1080/19490976.2015.1035855.
   Google Scholar
• Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017 Oct;7(1):13537. doi:10.1038/s41598-017-13601-y.
   Google Scholar
• Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013 Jun;144(7):1394–401, 1401.e1. doi:10.1053/j.gastro.2013.02.043.
   Google Scholar
• Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, Jafari P, Asemi Z. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36(5):1245–1249. doi:10.1016/j.clnu.2016.08.015.
   Google Scholar
• Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016 Nov;8:256. doi:10.3389/fnagi.2016.00256.
   Google Scholar
• Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z. Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(3):1031–1035. doi:10.1016/j.clnu.2018.05.018.
   Google Scholar
• Lum GR, Olson CA, Hsiao EY. Emerging roles for the intestinal microbiome in epilepsy. Neurobiol Dis. 2020 Feb;135:104576. doi:10.1016/j.nbd.2019.104576.
   Google Scholar
• Blacher E, Levy M, Tatirovsky E, Elinav E. Microbiome-modulated metabolites at the interface of host immunity. J Immunol. 2017 Jan;198(2):572–580. doi:10.4049/jimmunol.1601247.
   Google Scholar
• Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014 May;38:1–12. doi:10.1016/j.bbi.2013.12.015.
   Google Scholar
• Wu S, Yi J, Zhang Y-G, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3(4):Apr. doi:10.14814/phy2.12356.
   Google Scholar
• Zhang Y-G, Wu S, Yi J, Xia Y, Jin D, Zhou J, Sun J. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017 Feb;39(2):322–336. doi:10.1016/j.clinthera.2016.12.014.
   Google Scholar
• Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, Chen T. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front Microbiol. 2016 Sep;7:1479. doi:10.3389/fmicb.2016.01479.
   Google Scholar
• Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, Ludolph AC, Weishaupt JH. The fecal microbiome of ALS patients. Neurobiol Aging. 2018;61:132–137. doi:10.1016/j.neurobiolaging.2017.09.023.
   Google Scholar
• Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019 Jul;572(7770):474–480. doi:10.1038/s41586-019-1443-5.
   Google Scholar
• Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994 Jun;264(5166):1772–1775. doi:10.1126/science.8209258.
   Google Scholar
• Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007 Dec;73(23):7767–7770. doi:10.1128/AEM.01477-07.
   Google Scholar
• Figueroa-Romero C, Guo K, Murdock BJ, Paez-Colasante X, Bassis CM, Mikhail KA, Raue KD, Evans MC, Taubman GF, McDermott AJ, et al. Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice. Dis Model Mech. 2019 Nov;13(2). doi:10.1242/dmm.040832.
   Google Scholar
• Rowland LP. Ameliorating amyotrophic lateral sclerosis. N Engl J Med. 2010 Mar;362(10):953–954. doi:10.1056/NEJMcibr0912229.
   Google Scholar
• Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003 Apr;53(4):423–426. doi:10.1002/ana.10561.
   Google Scholar
• Mandrioli J, Amedei A, Cammarota G, Niccolai E, Zucchi E, D’Amico R, Ricci F, Quaranta G, Spanu T, Masucci L. FETR-ALS study protocol: a randomized clinical trial of fecal microbiota transplantation in amyotrophic lateral sclerosis. Front Neurol. 2019 Sep;10:1021. doi:10.3389/fneur.2019.01021.
   Google Scholar
• A study of protein metabolism, microbiome and investigational probiotic use in patients with ALS - full text view - clinicalTrials.gov. [Online]. [Accessed 21 Mar 2020]. https://clinicaltrials.gov/ct2/show/NCT03324399.
   Google Scholar
• Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol. Rep. 2017 Sep;5(18):e13443. doi:10.14814/phy2.13443.
   Google Scholar
• Zhai C-D, Zheng -J-J, An B-C, Huang H-F, Tan Z-C. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. Chin Med J (Engl). 2019 Aug;132(15):1815–1822. doi:10.1097/CM9.0000000000000351.
   Google Scholar
• Singh RK, Chang H-W, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017 Apr;15(1):73. doi:10.1186/s12967-017-1175-y.
   Google Scholar
• Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom management and end-of-life care in amyotrophic lateral sclerosis. Neurol Clin. 2015 Nov;33(4):889–908. doi:10.1016/j.ncl.2015.07.010.
   Google Scholar
• Bergendal B, McAllister A. Orofacial function and monitoring of oral care in amyotrophic lateral sclerosis. Acta Odontol Scand. 2017 Apr;75(3):179–185. doi:10.1080/00016357.2016.1276212.
   Google Scholar
• Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA. 2011 Sep;108(38):16050–16055. doi:10.1073/pnas.1102999108.
   Google Scholar
• Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell. 2018 May;9(5):488–500. doi:10.1007/s13238-018-0548-1.
   Google Scholar
• Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002 Jul;59(2):280–282. doi:10.1212/WNL.59.2.280.
   Google Scholar
• ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015 Jul;14(7):702–709. DOI:10.1016/S1474-4422(15)00104-0.
   Google Scholar
• Chen JH, Wu SC, Chen HJ, Kao CH, Tseng CH, Tsai CH. Risk of developing pressure sore in amyotrophic lateral sclerosis patients - a nationwide cohort study. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1589–1596. doi:10.1111/jdv.14911.
   Google Scholar
• Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010 Nov;156(Pt 11):3216–3223. doi:10.1099/mic.0.040618-0.
   Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Eurals Consortium. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Dec;10(5–6):310–323. doi:10.3109/17482960802566824.
   Google Scholar
• Corcia P, Pradat P-F, Salachas F, Bruneteau G, le Forestier N, Seilhean D, Hauw -J-J, Meininger V. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler. 2008;9(1):59–62. doi:10.1080/17482960701656940.
   Google Scholar
• Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018 Mar;17(5):423–433. doi:10.1016/S1474-4422(18)30089-9.
   Google Scholar
• Kim S, Chung SE, Lee S, Park J, Choi S, Kim S. Experience of complementary and alternative medicine in patients with amyotrophic lateral sclerosis and their families: A qualitative study. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jan;17(3–4):191–197. doi:10.3109/21678421.2015.1125504.
   Google Scholar
• Adams J, Lee M, Peng W. Critical review of complementary and alternative medicine use in amyotrophic lateral sclerosis: prevalence and users’ profile, decision-making, information seeking, and disclosure in the face of a lack of efficacy. Neurodegener Dis. 2018 Sep;18(4):225–232. doi:10.1159/000492946.
   Google Scholar
• Toepfer M, Folwaczny C, Klauser A, Riepl RL, Müller-Felber W, Pongratz D. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999 Dec;1(1):15–19. doi:10.1080/146608299300079484.
   Google Scholar
• Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019 Feb;18(2):211–220. doi:10.1016/S1474-4422(18)30394-6.
   Google Scholar
• Tropini C, Moss EL, Merrill BD, Ng KM, Higginbottom SK, Casavant EP, Gonzalez CG, Fremin B, Bouley DM, Elias JE, et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. Cell. 2018 Jun;173(7):1742–1754.e17. doi:10.1016/j.cell.2018.05.008.
   Google Scholar
• Cooper-Knock J, Robins H, Niedermoser I, Wyles M, Heath PR, Higginbottom A, Walsh T, Kazoka M, Project MinE ALS Sequencing Consortium, P. G. Ince, G. M. Hautbergue, C. J. McDermott, J. Kirby, and P. J. Shaw. Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front Mol Neurosci. 2017 Nov;10:370. doi:10.3389/fnmol.2017.00370.
   Google Scholar
• Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, Mitra RD, Ravits J, Harms MB, Baloh RH. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015 Jan;77(1):100–113. doi:10.1002/ana.24306.
   Google Scholar
• Kioumourtzoglou M-A, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015 Aug;72(8):905–911. doi:10.1001/jamaneurol.2015.0910.
   Google Scholar
• O’Reilly ÉJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, Thun M, Park Y, Kolonel LN, Ascherio A. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):205–211. doi:10.3109/21678421.2012.735240.
   Google Scholar
• Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008 Mar;70(13):1004–1009. doi:10.1212/01.wnl.0000285080.70324.27.
   Google Scholar
• Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011 Jan;10(1):75–82. doi:10.1016/S1474-4422(10)70224-6.
   Google Scholar
• Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, et al. Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1229–1233. doi:10.1136/jnnp-2016-313793.
   Google Scholar
• Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006 Dec;444(7122):1027–1031. doi:10.1038/nature05414.
   Google Scholar
• Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018 Mar;359(6380):1151–1156. doi:10.1126/science.aao5774.
   Google Scholar
• Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås-Holm L, Wu H, Carreras A, Jeong H, Olofsson LE, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018 Nov;175(4):947–961.e17. doi:10.1016/j.cell.2018.09.055.
   Google Scholar
• Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto J-M, Kennedy S, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug;500(7464):541–546. DOI:10.1038/nature12506.
   Google Scholar
• Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096–1103. doi:10.1038/s41591-019-0495-2.
   Google Scholar
• Shanahan ER, Shah A, Koloski N, Walker MM, Talley NJ, Morrison M, Holtmann GJ. Influence of cigarette smoking on the human duodenal mucosa-associated microbiota. Microbiome. 2018 Aug;6(1):150. doi:10.1186/s40168-018-0531-3.
   Google Scholar
• Suez J, Korem T, Zilberman-Schapira G, Segal E, Elinav E. Non-caloric artificial sweeteners and the microbiome: findings and challenges. Gut Microbes. 2015 Apr;6(2):149–155. doi:10.1080/19490976.2015.1017700.
   Google Scholar
• Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct;514(7521):181–186. doi:10.1038/nature13793.
   Google Scholar
• Gotkine M, Friedlander Y, Hochner H. Triathletes are over-represented in a population of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7–8):534–536. doi:10.3109/21678421.2014.932383.
   Google Scholar
• Huisman MHB, Seelen M, de Jong SW, Dorresteijn KRIS, van Doormaal PTC, van der Kooi AJ, de Visser M, Schelhaas HJ, van den Berg LH, Veldink JH. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):976–981. doi:10.1136/jnnp-2012-304724.
   Google Scholar
• Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, Zagai U, Pawitan Y, Fang F. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019 Nov;26(11):1355–1361. doi:10.1111/ene.13986.
   Google Scholar
• Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis SM, Gurney ME. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci. 1995 Aug;6(4):349–362. doi:10.1006/mcne.1995.1027.
   Google Scholar
• Dodiya HB, Kuntz T, Shaik SM, Baufeld C, Leibowitz J, Zhang X, Gottel N, Zhang X, Butovsky O, Gilbert JA, et al. Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes. J Exp Med. 2019 Jul;216(7):1542–1560. doi:10.1084/jem.20182386.
   Google Scholar
• Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, et al. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017 Feb;32(5):739–749. doi:10.1002/mds.26942.
   Google Scholar
• Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA. 2017 Oct;114(40):10713–10718. doi:10.1073/pnas.1711235114.
   Google Scholar
• Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA. 2017 Oct;114(40):10719–10724. doi:10.1073/pnas.1711233114.
   Google Scholar